Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Increases By 158.1%

HCW Biologics Inc. (NASDAQ:HCWB) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totaling 110,641 shares, a growth of 158.1% from the March 15th total of 42,868 shares. Based on an average trading volume of 41,337,246 shares, the short-interest ratio is presently 0.0 days. Approximately 5.5% of the shares of the company are short sold.

HCW Biologics Trading Down 3.4%

HCW Biologics stock opened at $0.35 on Tuesday. HCW Biologics has a 12 month low of $0.25 and a 12 month high of $17.80. The business’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $1.79. The company has a market cap of $2.37 million, a price-to-earnings ratio of -0.04 and a beta of 0.90.

HCW Biologics (NASDAQ:HCWB) last posted its quarterly earnings data on Tuesday, March 31st. The company reported ($2.63) EPS for the quarter, missing the consensus estimate of ($0.84) by ($1.79). The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $7.01 million.

Hedge Funds Weigh In On HCW Biologics

An institutional investor recently bought a new position in HCW Biologics stock. Armistice Capital LLC bought a new position in shares of HCW Biologics Inc. (NASDAQ:HCWB) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics as of its most recent SEC filing. 2.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $35.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.